Well look at it this way they providing Avelumab for the study, saving Imugene some $ along the way. The fact that they willing to provide Avelumab free for this study says a lot already as it is a Phase 2 study. Not only are they providing Avelumab, they are also willing to put their name to it and be associated with the study by announcing it to the world.
If this works; we do not even have to imagine what will happen, we know what will happen.
Great result by Leslie and her team once again.
Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-42
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.001(1.82%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.4¢ | $443.4K | 8.072M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 3056419 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |